Video_1_Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer.mp4

The surgical management of advanced ovarian cancer has historically emphasized an open technique, but advances in minimally invasive surgery (MIS) have led to its increasing use in ovarian cancer. Most research has focused on the utility of MIS in the interval debulking setting. Here, we present a case of a 38-year-old patient with incidentally diagnosed advanced stage ovarian cancer. We describe the robotic surgery techniques used to achieve complete primary cytoreduction, including resection of disease on the diaphragm. The patient has completed standard adjuvant chemotherapy and maintenance treatment and remains without evidence of disease for more than 2 years. This case details the techniques utilized to achieve complete cytoreduction including trocar placement, robotic instrument preference, and rotation of the robotic boom. This patient has had successful perioperative and oncologic outcomes, and her case highlights the role for minimally invasive primary debulking surgery for select patients with advanced ovarian cancer.</p

Video_2_Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer.mp4

The surgical management of advanced ovarian cancer has historically emphasized an open technique, but advances in minimally invasive surgery (MIS) have led to its increasing use in ovarian cancer. Most research has focused on the utility of MIS in the interval debulking setting. Here, we present a case of a 38-year-old patient with incidentally diagnosed advanced stage ovarian cancer. We describe the robotic surgery techniques used to achieve complete primary cytoreduction, including resection of disease on the diaphragm. The patient has completed standard adjuvant chemotherapy and maintenance treatment and remains without evidence of disease for more than 2 years. This case details the techniques utilized to achieve complete cytoreduction including trocar placement, robotic instrument preference, and rotation of the robotic boom. This patient has had successful perioperative and oncologic outcomes, and her case highlights the role for minimally invasive primary debulking surgery for select patients with advanced ovarian cancer.</p

, Mean tumor volumes and estimated ID8 tumor growth curves in control mice or mice treated with paclitaxel, SU5416 or their combination

<p><b>Copyright information:</b></p><p>Taken from "Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer"</p><p>http://www.translational-medicine.com/content/6/1/2</p><p>Journal of Translational Medicine 2008;6():2-2.</p><p>Published online 8 Jan 2008</p><p>PMCID:PMC2235830.</p><p></p> , Estimated difference between the observed mean tumor volume in animals receiving combined paclitaxel/SU5416 therapy and a predicted tumor volume assuming additive effects for the two individual drugs with 95% confidence intervals

, Examples of microvascular density in ID8-Vegf tumors of control mice or mice treated with SU5416, paclitaxel or combination

<p><b>Copyright information:</b></p><p>Taken from "Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer"</p><p>http://www.translational-medicine.com/content/6/1/2</p><p>Journal of Translational Medicine 2008;6():2-2.</p><p>Published online 8 Jan 2008</p><p>PMCID:PMC2235830.</p><p></p> Vessels were visualized with CD31 immunostaining. Four tumor microphotographs are combined for each treatment. 200× magnification. , Microvascular density quantification in ID8-Vegf tumors of control mice or mice treated with SU5416, paclitaxel or combination. * indicates p ≤ 0.05

, Mean tumor volumes and estimated ID8-Vegf tumor growth curves in control mice or mice treated with paclitaxel, SU5416 or combination

<p><b>Copyright information:</b></p><p>Taken from "Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer"</p><p>http://www.translational-medicine.com/content/6/1/2</p><p>Journal of Translational Medicine 2008;6():2-2.</p><p>Published online 8 Jan 2008</p><p>PMCID:PMC2235830.</p><p></p> , Estimated difference between the observed mean tumor volume in animals receiving combined paclitaxel/SU5416 therapy and a predicted tumor volume assuming additive effects to the two individual drugs with 95% confidence intervals

, Examples of microvascular density in ID8 tumors of control mice or mice treated with SU5416, paclitaxel or combination

<p><b>Copyright information:</b></p><p>Taken from "Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer"</p><p>http://www.translational-medicine.com/content/6/1/2</p><p>Journal of Translational Medicine 2008;6():2-2.</p><p>Published online 8 Jan 2008</p><p>PMCID:PMC2235830.</p><p></p> Vessels were visualized with CD31 immunostaining. Four tumor microphotographs are combined for each treatment. 200× magnification. , Microvascular density quantification in ID8 tumors of control mice or mice treated with SU5416, paclitaxel or combination. * indicates p ≤ 0.05